Pharmaceutical Intermediate Quality: Beyond the CoA

Beyond the CoA: What Buyers Should Verify When Sourcing Pharmaceutical Intermediates

A certificate of analysis is essential, but it is not the whole quality story. Learn what buyers should verify about identity, methods, impurities, traceability and change control when sourcing pharmaceutical intermediates.

A certificate of analysis is an essential batch document, but it is not the complete quality story. Buyers of pharmaceutical intermediates also need to understand identity, methods, impurity context, traceability and the changes that could affect future batches.

A CoA is a starting point, not a complete qualification

A certificate of analysis records results for a defined batch against an agreed specification. It can confirm that selected tests were performed and that reported results met the stated limits. What it does not automatically establish is whether the specification is appropriate for the buyer’s intended use, whether the methods are sufficiently specific, or whether the batch is representative of material that will be supplied later.

This distinction matters for pharmaceutical intermediates because the next synthetic step may be sensitive to attributes that are not visible in a headline purity result. A trace isomer, residual reagent, water level, inorganic residue or change in physical form may influence reaction performance, work-up, isolation or the downstream impurity profile.

The right evidence package is therefore risk-based. Material for exploratory research and material entering a regulated manufacturing process will not necessarily require the same controls. The starting point should always be a clear definition of intended use, development stage and the attributes that could affect the next operation.

Begin with unambiguous material identity

Before comparing test results, confirm that every document refers to the same material. A CAS number can be useful, but it may not capture salt form, solvate or hydrate state, stereochemistry, isotopic form or a specific composition. The material name, molecular structure, formula and relevant form should be aligned across the quotation, specification, label, CoA and technical records.

For chiral intermediates, chemical identity and stereochemical identity are separate questions. A sample may show high chemical purity while containing an unacceptable level of the opposite enantiomer or another diastereomer. Where stereochemistry carries into later steps, the specification and analytical approach should address it explicitly.

Batch and packaging identifiers should also connect the physical container to the CoA and the supplier’s records. Ambiguous naming or relabelling can create avoidable investigation work even when the underlying chemistry is correct.

Understand what each number actually measures

“Purity” can refer to different measurements. A chromatographic area percentage is not necessarily the same as an assay expressed on a mass basis. Detector response can vary among the main component and its impurities, while water, residual solvents, inorganic material or counterions may not be represented by a single chromatographic value.

Useful review questions include:

Is the reported result an assay, area percentage or another measurement?
Which analytical method and detector were used?
Is the method suitable for relevant isomers, degradants or closely related compounds?
Are units, calculation basis and acceptance criteria unambiguous?
Were water, residual solvents or inorganic residues assessed separately where relevant?

The level of method information needed will depend on the project. Buyers do not always need a complete method-validation package, but they should understand enough to judge whether the reported result answers the intended quality question.

Look beyond headline purity to the impurity profile

Two batches can show the same nominal purity while containing different impurities. Starting materials, reagents, catalysts, solvents, side reactions, degradation and purification choices can each shape the profile. An unknown peak may be less important in one downstream route and highly consequential in another.

A practical discussion should connect observed impurities with the manufacturing route and the material’s intended use. This does not mean that every trace component requires full identification. It means that known and credible risks should be considered scientifically, and that unexpected differences should be investigated rather than hidden behind a single total-purity number.

Where applicable, the assessment may include related substances, residual solvents, elemental or catalyst residues, water, inorganic content, stereoisomers and specific process-related impurities. Additional risks—such as mutagenic impurities or nitrosamines—should be evaluated only where the route, materials and intended use make them relevant. There is no universal test panel that fits every intermediate.

Connect the document to the original manufacturer and batch

A supply chain may include a manufacturer, distributor, repackager, testing laboratory and importer. The CoA should make clear which organization manufactured the material, which party sampled and tested it, and which party released the batch. When a distributor issues its own document, the relationship to the original manufacturer’s data should be understood.

Traceability also includes storage, packaging and transport conditions where these may influence stability or usability. A valid result at release does not by itself show that the material remained suitable after inappropriate storage or repackaging.

Initial sample evaluation can provide valuable evidence, but the sample should be representative of the proposed commercial source and route. A development sample made by a different process may not predict the impurity profile or handling characteristics of routine batches.

Change control keeps the evidence current

Qualification is not a one-time review. A change in manufacturing site, synthetic route, critical raw material, reagent grade, solvent-recovery practice, purification, analytical method, packaging or storage can alter material performance even when the product name and specification remain unchanged.

A written technical or quality agreement can define which changes require notification, how responsibilities are divided and what information will support continued suitability. The commercial contract and the quality agreement serve different purposes and should be aligned.

Ongoing review can consider batch consistency, deviations, complaints, analytical discrepancies, responsiveness and the reliability of change communication. The depth and frequency of review should remain proportionate to material risk and intended use.

A practical evidence package for intermediate sourcing

Depending on project stage and risk, a useful package may include:

Confirmed chemical and stereochemical identity
An agreed specification with clear units and test methods
A batch-specific CoA and representative analytical data
Relevant impurity and residual-solvent information
Identification of the original manufacturer and testing responsibility
Storage, packaging, retest or expiry information where applicable
Defined deviation, complaint and change-notification contacts
A representative sample or confirmatory testing plan when justified

The objective is not to collect the largest possible document set. It is to obtain evidence that answers the material-specific questions most likely to affect the next step.

What this means for Rlavie customers

For catalogue and custom-synthesis enquiries, early discussion of intended use, target specification, analytical expectations, quantity and documentation can reduce later ambiguity. Rlavie can discuss project-specific requirements before work begins; customers remain responsible for qualifying each material and supplier for their own use and applicable quality framework.

Explore Rlavie’s Custom Synthesis service or review the company’s technical capabilities.

Conclusion

A CoA is valuable because it records defined batch results. Its limitations appear when it is treated as a substitute for material understanding. Reliable sourcing connects the CoA with unambiguous identity, suitable methods, impurity context, batch traceability and change control.

For pharmaceutical intermediates, the most useful question is not simply “Does the batch pass?” It is “Does the available evidence show that this material is fit for the next intended step?”

This article is for general industry information and does not constitute regulatory, quality or legal advice.